Opus Genetics (IRD) Expected to Announce Quarterly Earnings on Thursday

Opus Genetics (NASDAQ:IRD) is anticipated to issue its quarterly earnings data on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $11.10 million for the quarter.

Opus Genetics Stock Up 2.9 %

NASDAQ:IRD opened at $1.07 on Thursday. The company has a 50 day simple moving average of $1.16. The company has a market capitalization of $33.78 million, a price-to-earnings ratio of -0.98 and a beta of 0.16. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $2.65.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a research note on Wednesday, February 19th.

Insider Transactions at Opus Genetics

In related news, CEO George Magrath purchased 100,000 shares of Opus Genetics stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the transaction, the chief executive officer now directly owns 599,150 shares of the company’s stock, valued at $587,167. This represents a 20.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.